Clinical Trials Logo

Clinical Trial Summary

The aim of the study was to use probiotic beauty products for 4 weeks and evaluate the impact of products on healthy skin.


Clinical Trial Description

Twenty subjects were recruited and informed to apply the lotion gel twice per day (3~5 mg/cm2 once) for 4 weeks. Two kinds of facial lotiongels, "A" gel and "B" gel, were provided to every subject. The "A" gel (TAC/Collagen lotiongel) was applied on subjects' right face and the "B" gel (placebo lotion) on their left face (formula showed as Table S2). Ordinary cosmetics usage was permitted but any change of usage was not allowed during the intervention. Outdoor activities (sun exposure) and the usage of sunscreen lotion were not limited in this study. Every subject was required to inspect his/her skin condition on week 0 and 4. Before inspection, the face was washed with water and waited for 30 min in an air-conditioned room (25°C, humility 55 ± 5%). Among these 20 subjects, eight of them had severe acne with at least two acne lesions on each side of face when participating this trial. They were instructed for more visits to evaluate the symptom of acne on week 1 and 2. Skin hydration (Corneometer CM825, Courage + Khazaka Electroni, Germany), sebum (Callegari 1930, Italy), and inflammation detection (Chroma Meter MM-500, Minolta, Japan) of upper cheek were measured in every subject. The improvement in inflammation was positively correlated with a decrease of a* value or an increase of L* value. VISIA® Complexion Analysis (VISIA® Complexion Analysis, U.S.A.) was also employed to measure the skin inflammation, porphyrins numbers and brown spot numbers of whole face. The result was presented as the mean value and the relative percentage (%) to the baseline. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05276661
Study type Interventional
Source Chia Nan University of Pharmacy & Science
Contact
Status Completed
Phase N/A
Start date May 18, 2020
Completion date August 15, 2020

See also
  Status Clinical Trial Phase
Completed NCT05038982 - Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin Phase 2
Completed NCT03563066 - Effect of Benralizumab in Atopic Dermatitis Phase 2
Recruiting NCT04818138 - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort N/A
Recruiting NCT05102396 - Topical Oxybutynin for Treatment of Hyperidrosis: Local or Systemic Effect? Phase 2
Completed NCT02916888 - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists N/A
Completed NCT00772447 - China Registration Study in Patients With Skin Infections Phase 3
Recruiting NCT01631617 - Effects of Treatments on Atopic Dermatitis Phase 2
Active, not recruiting NCT04971200 - Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo Early Phase 1
Completed NCT04144491 - Effect of L. Rhamnosus Yoba on RTI and Other Health Outcomes Among Children (3-6 Years) in Uganda N/A
Recruiting NCT04138342 - Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer Phase 1
Recruiting NCT06061471 - To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis Phase 2
Terminated NCT04775316 - Prospective, International, Multicenter, Observational Study to Evaluate the Clinical Performance and Safety of a Silicone-coated Transparent Postoperative Dressing
Recruiting NCT05765461 - Effect of Lipikar Baume AP+M on Quality of Life and Pain of Adults With Dryness or Severe Xerosis
Withdrawn NCT04593914 - A Novel Skin Barrier Protectant for Acute Radiodermatitis N/A
Completed NCT03720470 - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Phase 3
Recruiting NCT06092866 - Digital Versus Telephone Symptom Assessment and Triage in Primary Care N/A
Recruiting NCT04901325 - Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) Phase 2
Recruiting NCT01917279 - Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC Phase 3
Completed NCT01975038 - Adaption of the Skin Sun Sensitivity Scale N/A
Recruiting NCT01427400 - The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction Phase 4